{"id":71436,"date":"2026-05-20T11:25:00","date_gmt":"2026-05-20T11:25:00","guid":{"rendered":"https:\/\/medsbase.com\/hcg-peptide\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"hcg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/hcg-peptide\/","title":{"rendered":"HCG (Choriongonadotropin) \u2014 V\u00fdzkumn\u00e1 kvalita"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je HCG (v\u00fdzkumn\u00e1 kvalita)?<\/h3>\n

HCG<\/strong> (Lidsk\u00fd choriov\u00fd gonadotropin) je glykoproteinov\u00fd hormon slo\u017een\u00fd ze dvou nekovalentn\u011b asociovan\u00fdch podjednotek (\u03b1, 92 aminokyselin \u2014 spole\u010dn\u00fdch s LH\/FSH\/TSH; \u03b2, 145 aminokyselin \u2014 specifick\u00fdch pro HCG), s p\u0159ibli\u017enou kombinovanou molekulovou hmotnost\u00ed ~36,7 kDa. Je to kanonick\u00fd farmakologick\u00fd n\u00e1stroj pro aktivaci receptoru LH\/CG (LHCGR)<\/strong> na Leydigov\u00fdch bu\u0148k\u00e1ch (stimulace produkce testosteronu u mu\u017esk\u00fdch v\u00fdzkumn\u00fdch model\u016f) a ovari\u00e1ln\u00edch theka \/ granul\u00f3zn\u00edch bu\u0148k\u00e1ch (stimulace folikul\u00e1rn\u00edho zr\u00e1n\u00ed a ovulace ve v\u00fdzkumu \u017eensk\u00e9 reprodukce). Zde dod\u00e1van\u00fd materi\u00e1l v\u00fdzkumn\u00e9 kvality je glykoforma extrahovan\u00e1 z mo\u010di (CAS 9002-61-3) s HPLC \u010distotou \u226599%, lyofilizovan\u00e1 ve vialk\u00e1ch 5 000 IU nebo 10 000 IU. Je funk\u010dn\u011b odli\u0161n\u00fd<\/em> od rekombinantn\u00edho rHCG (choriogonadotropin alfa, CAS 56832-30-5) pou\u017e\u00edvan\u00e9ho v n\u011bkter\u00fdch klinick\u00fdch p\u0159\u00edpravc\u00edch. Dod\u00e1v\u00e1no pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00fd HCG extrahovan\u00fd z mo\u010di s HPLC \u010distotou \u226599% \u00b7 COA dostupn\u00e9 na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 kur\u00fdrn\u00ed slu\u017eba pro v\u00fdzkumn\u00e9 dod\u00e1vky \u00b7 1 400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
T\u0159\u00edda slou\u010denin<\/strong><\/td>\nHeterodimern\u00ed glykoproteinov\u00fd hormon (\u03b1 + \u03b2 podjednotky); agonista receptoru LH\/CG (LHCGR); peptidov\u00fd hormon<\/td>\n<\/tr>\n
Chemick\u00fd n\u00e1zev<\/strong><\/td>\nHuman Chorionic Gonadotropin (extracted from urine; uHCG)<\/td>\n<\/tr>\n
CAS \u010d\u00edslo<\/strong><\/td>\n9002-61-3 (urinary HCG); 56832-30-5 (recombinant form \u2014 not the same as the natural one)<\/td>\n<\/tr>\n
Subunit Structure<\/strong><\/td>\nHeterodimer of two non-covalently associated subunits: \u03b1-subunit (92 amino acids, shared with LH\/FSH\/TSH) and \u03b2-subunit (145 amino acids, unique to HCG). Both subunits are extensively N- and O-glycosylated \u2014 the high sialic-acid content of \u03b2-subunit is responsible for HCG's exceptionally long plasma half-life relative to LH. Both subunits are extensively N- and O-glycosylated \u2014 the high sialic-acid content of \u03b2-subunit is responsible for HCG's exceptionally long plasma half-life relative to LH.<\/td>\n<\/tr>\n
item7<\/strong><\/td>\n~36,700 Da (~36.7 kDa) kombinovan\u00fd heterodimer; \u03b1-podjednotka ~14 kDa, \u03b2-podjednotka ~22 kDa (siln\u011b glykosylovan\u00fd)<\/td>\n<\/tr>\n
item2<\/strong><\/td>\nHeterodimern\u00ed glykoprotein \u2014 \u03b1-podjednotka (92 aminokyselin, spole\u010dn\u00e1 pro LH\/FSH\/TSH) + \u03b2-podjednotka (145 aminokyselin, specifick\u00e1 pro hCG). Siln\u00e1 sialylace (~30% w\/w sacharid\u016f) poskytuje plazmatick\u00fd polo\u010das 33\u201337 h. \u017d\u00e1dn\u00fd jednotn\u00fd molekulov\u00fd vzorec kv\u016fli variabiln\u00edmu slo\u017een\u00ed glykoforem; molekulov\u00e1 hmotnost samotn\u00e9ho proteinu ~25 kDa, pln\u011b glykosylovan\u00e1 molekulov\u00e1 hmotnost ~36,7 kDa.<\/td>\n<\/tr>\n
Mechanismus \u00fa\u010dinku<\/strong><\/td>\nV\u00e1\u017ee a aktivuje LH\/CG receptor (LHCGR<\/strong>) \u2014 Gs-sp\u0159a\u017een\u00fd GPCR exprimovan\u00fd na Leydigov\u00fdch bu\u0148k\u00e1ch (varle) a ovari\u00e1ln\u00edch theca \/ granulosa bu\u0148k\u00e1ch. Aktivace receptoru spou\u0161t\u00ed adenyl\u00e1tcykl\u00e1zu, zvy\u0161uje intracelul\u00e1rn\u00ed cAMP, aktivuje PKA a indukuje steroidogenn\u00ed enzymy (StAR, CYP17A1, CYP11A1), kter\u00e9 \u0159\u00edd\u00ed de-novo biosynt\u00e9zu testosteronu (mu\u017ei) nebo biosynt\u00e9zu estrogenu\/progesteronu (\u017eeny). HCG a LH sd\u00edlej\u00ed stejn\u00fd receptor a stejnou downstream kask\u00e1du.<\/td>\n<\/tr>\n
1,302 Da<\/strong><\/td>\n~9 300 IU na mg vysoce \u010di\u0161t\u011bn\u00e9ho materi\u00e1lu (referen\u010dn\u00ed standard WHO 5. mezin\u00e1rodn\u00ed standard). 1 IU tedy odpov\u00edd\u00e1 p\u0159ibli\u017en\u011b 108 ng \u010dist\u00e9ho peptidu. Lahvi\u010dka 5 000 IU obsahuje ~0,54 mg peptidu; lahvi\u010dka 10 000 IU obsahuje ~1,08 mg.<\/td>\n<\/tr>\n
Plazmatick\u00fd polo\u010das<\/strong><\/td>\nBif\u00e1zick\u00e1 eliminace \u2014 po\u010d\u00e1te\u010dn\u00ed f\u00e1ze ~6 h, termin\u00e1ln\u00ed f\u00e1ze 33\u201337 h. V\u00fdrazn\u011b del\u0161\u00ed ne\u017e u LH (~20 min) \u2014 zp\u016fsobeno vysok\u00fdm obsahem kyseliny sialov\u00e9 v glykanech \u03b2-podjednotky, co\u017e sni\u017euje jatern\u00ed clearance.<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd amorfn\u00ed pr\u00e1\u0161ek; jednor\u00e1zov\u00e9 v\u00fdzkumn\u00e9 lahvi\u010dky. Dod\u00e1v\u00e1no s odd\u011blen\u00fdm lyofilizovan\u00fdm kol\u00e1\u010dkem uzav\u0159en\u00fdm z\u00e1tkou (bez rozpou\u0161t\u011bdla v lahvi\u010dce).<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599 % (ov\u011b\u0159eno HPLC); WHO biotest potvrzuje afinitu k LHCGR v souladu s 5. mezin\u00e1rodn\u00edm standardem. Certifik\u00e1t anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nRekonstituujte v bakteriostatick\u00e9 vod\u011b (standardn\u00ed v\u00fdzkumn\u00e9 rozpou\u0161t\u011bdlo) v pom\u011bru 1,0 ml na 5 000 IU (\u2192 5 000 IU\/ml pracovn\u00ed roztok) nebo 2,0 ml na 10 000 IU (\u2192 5 000 IU\/ml); jin\u00e9 \u0159ed\u011bn\u00ed dle protokolu. Lyofilizovan\u00fd kol\u00e1\u010dek na b\u00e1zi mannitolu se rychle rozpou\u0161t\u00ed p\u0159i jemn\u00e9m krou\u017een\u00ed \u2014 net\u0159epat. Vyvarujte se vortexov\u00e1n\u00ed (vysok\u00e9 smykov\u00e9 s\u00edly mohou disociovat \u03b1\/\u03b2 heterodimer).<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00fd: 2\u20138 \u00b0C neotev\u0159en\u00fd pro kr\u00e1tkodob\u00e9 skladov\u00e1n\u00ed pracovn\u00edho roztoku; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed (stabilita \u226536 m\u011bs\u00edc\u016f p\u0159i \u221220 \u00b0C; \u226518 m\u011bs\u00edc\u016f p\u0159i 2\u20138 \u00b0C). Rekonstituovan\u00fd: 2\u20138 \u00b0C, pou\u017e\u00edt do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nezamrazujte rekonstituovan\u00fd materi\u00e1l.<\/strong> \u2014 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed disociuj\u00ed \u03b1\/\u03b2 heterodimer a ni\u010d\u00ed biologickou aktivitu.<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nepou\u017e\u00edvat pro hum\u00e1nn\u00ed nebo veterin\u00e1rn\u00ed diagnostick\u00e9 \u010di terapeutick\u00e9 \u00fa\u010dely. HCG je na seznamu zak\u00e1zan\u00fdch l\u00e1tek Sv\u011btov\u00e9 antidopingov\u00e9 agentury (WADA) (t\u0159\u00edda S2, peptidov\u00e9 hormony, r\u016fstov\u00e9 faktory a p\u0159\u00edbuzn\u00e9 l\u00e1tky) a je zak\u00e1z\u00e1no kdykoli u mu\u017esk\u00fdch sportovc\u016f (v\u00fdjimka pro sportovkyn\u011b odr\u00e1\u017e\u00ed roli HCG jako p\u0159irozen\u00e9ho t\u011bhotensk\u00e9ho hormonu). V\u00fdzkumn\u00edci pracuj\u00edc\u00ed s lidsk\u00fdmi subjekty by m\u011bli b\u00fdt v\u011bdomi tohoto regula\u010dn\u00edho statusu.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Co je HCG?<\/h2>\n

HCG<\/strong> (Chorionick\u00fd gonadotropin \u010dlov\u011bka, CAS 9002-61-3) je glykoproteinov\u00fd peptidov\u00fd hormon pat\u0159\u00edc\u00ed do stejn\u00e9 rodiny gonadotropin\u016f jako luteiniza\u010dn\u00ed hormon (LH), folikuly stimuluj\u00edc\u00ed hormon (FSH) a tyreoid\u00e1ln\u00ed stimuluj\u00edc\u00ed hormon (TSH). Stejn\u011b jako ostatn\u00ed t\u0159i je to heterodimer slo\u017een\u00fd z \u03b1-podjednotky (92 aminokyselin, identick\u00e9 u v\u0161ech \u010dty\u0159 hormon\u016f) a \u03b2-podjednotky (145 aminokyselin, specifick\u00e9 pro HCG). Podjednotky \u03b1 a \u03b2 jsou nekovalentn\u011b asociov\u00e1ny a ob\u011b jsou v\u00fdrazn\u011b glykosylov\u00e1ny \u2014 samotn\u00e1 \u03b2-podjednotka nese \u010dty\u0159i N-v\u00e1zan\u00e9 a \u010dty\u0159i O-v\u00e1zan\u00e9 glykany a vysok\u00fd obsah kyseliny sialov\u00e9 v t\u011bchto glykanech je zodpov\u011bdn\u00fd za v\u00fdjime\u010dn\u011b dlouh\u00fd polo\u010das HCG v plazm\u011b ve srovn\u00e1n\u00ed s LH (33\u201337 h termin\u00e1ln\u00ed f\u00e1ze oproti ~20 min u LH).<\/p>\n

Endogenn\u00ed HCG je produkov\u00e1n syncytiotrofoblastem vyv\u00edjej\u00edc\u00ed se placenty b\u011bhem t\u011bhotenstv\u00ed, kde udr\u017euje corpus luteum a produkci progesteronu po prvn\u00edch ~10 t\u00fddn\u016f gestace. Mimo t\u011bhotenstv\u00ed se norm\u00e1ln\u011b nevyskytuje v detekovateln\u00fdch hladin\u00e1ch; jeho p\u0159\u00edtomnost v s\u00e9ru nebo mo\u010di je proto z\u00e1kladem t\u011bhotensk\u00fdch test\u016f. Farmakologick\u00fd v\u00fdznam HCG ve v\u00fdzkumu v\u0161ak nesouvis\u00ed s touto fyziologickou rol\u00ed, ale s t\u00edm, \u017ee HCG v\u00e1\u017ee a aktivuje stejn\u00fd receptor LH\/CG (LHCGR) jako endogenn\u00ed LH \u2014 ale s mnohem del\u0161\u00ed dobou \u00fa\u010dinku. HCG je proto standardn\u00edm farmakologick\u00fdm n\u00e1strojem pro trvalou aktivaci LHCGR ve v\u00fdzkumu zam\u011b\u0159en\u00e9m na funkci Leydigov\u00fdch bun\u011bk, gon\u00e1d\u00e1ln\u00ed steroidogenezi, spermatogenezi, v\u00fdvoj folikul\u016f, ovulaci a \u0161ir\u0161\u00ed souvislosti osy HPG.<\/p>\n

V obchod\u011b existuj\u00ed dv\u011b molekul\u00e1rn\u00ed formy HCG: forma extrahovan\u00e1 z mo\u010di (uHCG<\/strong>, CAS 9002-61-3), \u010di\u0161t\u011bn\u00fd z mo\u010di t\u011bhotn\u00fdch \u017een, co\u017e je forma, kterou dod\u00e1v\u00e1me; a rekombinantn\u00ed forma (rHCG<\/strong> neboli choriogonadotropin alfa, CAS 56832-30-5), produkovan\u00e1 v CHO bu\u0148k\u00e1ch a pou\u017e\u00edvan\u00e1 v n\u011bkter\u00fdch klinick\u00fdch p\u0159\u00edpravc\u00edch (Ovidrel \/ Ovitrelle). Ob\u011b formy maj\u00ed stejnou aminokyselinovou sekvenci a stejn\u00fd vazebn\u00fd profil k LHCGR, ale glykyla\u010dn\u00ed vzorce se m\u00edrn\u011b li\u0161\u00ed mezi mo\u010dov\u011b extrahovanou formou a expres\u00ed v CHO bu\u0148k\u00e1ch \u2014 publikovan\u00e9 srovn\u00e1vac\u00ed bioassay uv\u00e1d\u011bj\u00ed \u0161iroce ekvivalentn\u00ed in-vivo \u00fa\u010dinnost.<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 aktivace receptoru LH\/CG a steroidogeneze<\/h2>\n

Mechanismus HCG pat\u0159\u00ed mezi nejl\u00e9pe charakterizovan\u00e9 v endokrinn\u00ed farmakologii:<\/p>\n